Key Inclusions
- A detailed assessment of the current market landscape of approved antibiotic generics, including information on drug developers, year of approval, region(s) of approval, type of antibiotic (based on chemical structure and drug class), mechanism of action (alteration of cell membranes, cell wall synthesis inhibition, mycolic acid synthesis inhibition, nucleic acid synthesis inhibition, protein synthesis inhibition and RNA polymerase inhibition), spectrum of activity (broad spectrum, extended spectrum and narrow spectrum), type of target bacteria (gram negative and gram positive), target bacterial strain(s), target diseases indication(s), nature of source (semi-synthetic and synthetic), type of therapy (combination therapy and monotherapy), route(s) of administration (intramuscular, intravenous, oral, topical and others / unspecified), dosage form(s) (capsules, creams, liquids, powder, tablets and others), and type of patient population (based on age and gender).
- A detailed assessment of the current market landscape of approved antibiotic brands, including information on drug developers, year of approval, region(s) of approval, type of antibiotic (based on chemical structure and drug class), mechanism of action (alteration of cell membranes, cell wall synthesis inhibition, mycolic acid synthesis inhibition, nucleic acid synthesis inhibition, protein synthesis inhibition and RNA polymerase inhibition), spectrum of activity (broad spectrum, extended spectrum and narrow spectrum), type of target bacteria (gram negative and gram positive), target bacterial strain(s), target diseases indication(s), nature of source (semi-synthetic and synthetic), type of therapy (combination therapy and monotherapy), route(s) of administration (intramuscular, intravenous, oral, topical and others / unspecified), dosage form(s) (capsules, creams, liquids, powder, tablets and others), type of patient population (based on age and gender) and type of innovation.
- A detailed assessment of the overall market landscape of clinical-stage antibiotics, including information on drug developers, status of development (clinical and preclinical), stage of development, type of antibiotic (based on chemical structure and drug class), mechanism of action (cell membrane alteration, cell wall synthesis inhibition, FABI inhibition, fatty acid synthesis inhibition, nucleic acid synthesis inhibition, protein synthesis inhibition and others), spectrum of activity (broad spectrum, extended spectrum and narrow spectrum), type of target bacteria (gram negative and gram positive), target bacterial strain(s), target disease indication(s), therapeutic area(s) (genetic disorder, immunological disorder, infectious disease, oncological disorder, renal disorder and sexually transmitted disease), nature of source (semi-synthetic and synthetic), type of therapy (combination therapy and monotherapy), route(s) of administration (intramuscular, intravenous, oral and others / unspecified), dosage form(s) (capsules, liquids, tablets and others / unspecified), dosage strength, dosage frequency, dosing period, type of patient population (based on age and gender).
- Elaborate profiles of key players engaged in the development of antibiotics (shortlisted based on proprietary criterion), including a brief overview of the company, key executives, financial information (if available), product portfolio, recent developments and an informed future outlook. In addition, the chapter highlights the key strategies and key focus areas of the developers, along with expert opinion.
- A detailed analysis of partnerships inked between stakeholders engaged in this domain, since 2017, based on several relevant parameters, such as year of partnership, type of partnership (acquisitions, commercialization agreements, distribution agreements, joint development agreements, licensing agreements, manufacturing agreements, product development agreements, product development and commercialization agreements, research and development agreements, technology utilization agreements and others), type of partner, company size, most active players (in terms of number of partnerships) and regional distribution of partnership activity in this domain.
- A detailed analysis of completed and ongoing clinical studies related to antibiotics, based on several relevant parameters, such as trial registration year, trial status, trial phase, type of patient population (based on gender), key focus areas, type of sponsor, geography and most active industry and non-industry players (in terms of number of trials).
- An insightful analysis, highlighting the key opinion leaders (KOLs) investigating clinical trials related to antibiotics, based on several relevant parameters, such as type of KOL, qualification, type of organization, affiliated organization, geographical location of KOLs and target disease indication(s). In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
- An elaborate discussion on key trends within the antibiotics industry providing insights on drug-pricing, outsourcing trends and impact of COVID-19 on the antibiotics domain.
- An insightful success protocol analysis of recently approved antibiotics, based on several relevant parameters, such as dosing frequency, drug efficacy, geographical reach, inter-class competition, intra-class competition, innovation feature, price, prevalence, route of administration, spectrum of activity, type of therapy and type of target bacteria
- Informed estimates of the existing market size and the future opportunity for global antibiotics market, over the next decade. Based on multiple parameters, such as drug class, mechanism of action, nature of source, target disease indication, type of therapy, routes of administration and key geographical regions. We have provided informed estimates on the evolution of the market for the period 2020-2030.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
- Type of Drug Class
- Tetracyclines
- Aminoglycosides
- Lincosamides
- Carbapenems
- Lipoglycopeptides
- Cephalosporins
- Fluoroquinolones
- Triazaacenaphthylenes
- Other Drug Classes
- Mechanism of Action
- Protein Synthesis Inhibition
- Cell Wall Synthesis Inhibition
- Nucleic Acid Synthesis Inhibition
- DNA Synthesis Inhibition
- Mycolic Acid Synthesis Inhibition
- Nature of Source
- Semi-synthetic
- Synthetic
- Target Disease Indication
- Respiratory Tract Infections
- Dermatological Infections
- Urinary Tract Infections
- Sexually Transmitted Infections
- Gastrointestinal Infections
- Hematological Infections
- Ear Infections
- Cystitis
- Diabetic Foot Infections
- Other Bacterial Infections
- Type of Therapy
- Monotherapies
- Combination Therapies
- Route of Administration
- Intravenous
- Oral
- Intravenous / Oral
- Key Geographical Regions
- North America
- Europe
- Asia Pacific
- MENA
- Latin America
Key Questions Answered
- Who are the leading players involved in the development of antibiotics?
- Which popular therapeutic areas are being targeted by clinical-stage antibiotics?
- What is the focus area of the ongoing research activity in the antibiotics domain?
- What types of partnership models are commonly adopted by stakeholders in this industry?
- What are the crucial factors that impact the sales of antibiotics?
- Who are the major key opinion leaders in the antibiotics domain?
- What are the key market trends and driving factors that are likely to impact this market?
- What is the current / likely future global antibiotics market size?
- Which drug class accounts for the largest share within the antibiotics market?
- Which region captures the largest share of the antibiotic market?
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/global-antibiotics-market.html
Learn from experts: do you know about these emerging industry trends?
Introduction To Exosome Therapeutics
Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
